A Study of IMC-1 In Patients With Fibromyalgia
| Status: | Completed |
|---|---|
| Conditions: | Chronic Pain, Chronic Pain, Fibromyalgia, Pain |
| Therapuetic Areas: | Musculoskeletal, Rheumatology |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 10/19/2013 |
| Start Date: | May 2013 |
| End Date: | May 2014 |
| Contact: | Mark Schmal |
| Email: | mark.schmal@premier-research.com |
A Double-Blinded, Randomized, Placebo-Controlled, Proof of Concept Phase 2a Study Exploring the Safety and Efficacy of IMC-1 for the Treatment of Patients With Fibromyalgia
This is a randomized, double-blind, placebo-controlled, 16-week study designed to evaluate
the hypothesis that tissue-resident herpes virus may be causally related to fibromyalgia
symptoms or recurrence. IMC-1 is a combination treatment that is designed to suppress this
suspected virus and thus alleviate fibromyalgia symptoms.
Inclusion Criteria:
- Diagnosis of fibromyalgia
- English speaker
Exclusion Criteria:
- Rheumatologic diseases
- Bipolar disease, OCD, severe anxiety, schizophrenia
- Systemic infection, severe cardiac disease, chronic steroid usage
- chronic opioid usage
We found this trial at
8
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials